However, inconsistent results have been reported, particularly in the second-line setting where high tumour PD-L1 expression has been shown to enrich for response to nivolumab [12] and durvalumab [8, 10] but not to pembrolizumab [7] or atezolizumab [9]. This evidence concerns the gene CD274 and neoplasm.